- Home
- TCRX
as 05-30-2025 3:42pm EST
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 90.5M | IPO Year: | 2021 |
| Target Price: | $9.50 | AVG Volume (30 days): | 774.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.02 - $9.29 | Next Earning Date: | 05-06-2025 |
| Revenue: | $4,421,000 | Revenue Growth: | -70.15% |
| Revenue Growth (this year): | 68.86% | Revenue Growth (next year): | 14.01% |
Stock Insider Trading Activity of TScan Therapeutics Inc. (TCRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | TCRX | 10% Owner | May 19 '25 | Buy | $1.20 | 2,588,794 | $3,106,552.80 | 6,746,141 |
Latest TScan Therapeutics Inc. News
TCRX Breaking Stock News: Dive into TCRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
Zacks
25 days ago
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
25 days ago
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
a month ago
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
GlobeNewswire
2 months ago
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
2 months ago
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
Simply Wall St.
3 months ago
TScan Therapeutics Full Year 2024 Earnings: Misses Expectations
Zacks
3 months ago
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
Compare TCRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TCRX TScan Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.